New subgroup analysis from the Phase 3 monarchE trial that explores outcomes by nodal status for Verzenio plus endocrine therapy in HR+, HER2– high-risk early breast cancer INDIANAPOLIS, Nov. 24, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback